|
1
|
Shern JF, Chen L, Chmielecki J, Wei JS,
Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et
al: Comprehensive genomic analysis of rhabdomyosarcoma reveals a
landscape of alterations affecting a common genetic axis in
fusion-positive and fusion-negative tumors. Cancer Discov.
4:216–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun X, Guo W, Shen JK, Mankin HJ, Hornicek
FJ and Duan Z: Rhabdomyosarcoma: Advances in molecular and cellular
biology. Sarcoma. 2015:2320102015. View Article : Google Scholar
|
|
3
|
Chardin P, Yeramian P, Madaule P and
Tavitian A: N-ras gene activation in the RD human rhabdomyosarcoma
cell line. Int J Cancer. 35:647–652. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Felix CA, Kappel CC, Mitsudomi T, Nau MM,
Tsokos M, Crouch GD, Nisen PD, Winick NJ and Helman LJ: Frequency
and diversity of p53 mutations in childhood rhabdomyosarcoma.
Cancer Res. 52:2243–2247. 1992.PubMed/NCBI
|
|
5
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar
|
|
6
|
Rodriguez-Viciana P, Warne PH, Dhand R,
Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD and Downward J:
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature.
370:527–532. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Castellano E and Downward J: RAS
Interaction with PI3K: More than just another effector pathway.
Genes Cancer. 2:261–274. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pylayeva-Gupta Y, Grabocka E and Bar-Sagi
D: RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer.
11:761–774. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Puri PL, Wu Z, Zhang P, Wood LD, Bhakta
KS, Han J, Feramisco JR, Karin M and Wang JY: Induction of terminal
differentiation by constitutive activation of p38 MAP kinase in
human rhabdomyosarcoma cells. Genes Dev. 14:574–584. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lluís F, Perdiguero E, Nebreda AR and
Muñoz-Cánoves P: Regulation of skeletal muscle gene expression by
p38 MAP kinases. Trends Cell Biol. 16:36–44. 2006. View Article : Google Scholar
|
|
12
|
Martínez-Limón A, Joaquin M, Caballero M,
Posas F and de Nadal E: The p38 pathway: From biology to cancer
therapy. Int J Mol Sci. 21:19132020. View Article : Google Scholar
|
|
13
|
Mauro A, Ciccarelli C, De Cesaris P,
Scoglio A, Bouché M, Molinaro M, Aquino A and Zani BM:
PKCalpha-mediated ERK, JNK and p38 activation regulates the
myogenic program in human rhabdomyosarcoma cells. J Cell Sci.
115:3587–3599. 2002. View Article : Google Scholar
|
|
14
|
Marampon F, Ciccarelli C and Zani BM:
Down-regulation of c-Myc following MEK/ERK inhibition halts the
expression of malignant phenotype in rhabdomyosarcoma and in non
muscle-derived human tumors. Mol Cancer. 5:312006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malempati S, Tibbitts D, Cunningham M,
Akkari Y, Olson S, Fan G and Sears RC: Aberrant stabilization of
c-Myc protein in some lymphoblastic leukemias. Leukemia.
20:1572–1581. 2006. View Article : Google Scholar
|
|
16
|
Gartel AL and Shchors K: Mechanisms of
c-myc-mediated transcriptional repression of growth arrest genes.
Exp Cell Res. 283:17–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iavarone A and Lasorella A: Myc and
differentiation: Going against the current. EMBO Rep. 15:324–325.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zinin N, Adameyko I, Wilhelm M, Fritz N,
Uhlen P, Ernfors P and Henriksson MA: MYC proteins promote neuronal
differentiation by controlling the mode of progenitor cell
division. EMBO Rep. 15:383–391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sears R, Leone G, DeGregori J and Nevins
JR: Ras enhances Myc protein stability. Mol Cell. 3:169–179. 1999.
View Article : Google Scholar
|
|
20
|
Megiorni F, Camero S, Ceccarelli S,
McDowell HP, Mannarino O, Marampon F, Pizer B, Shukla R, Pizzuti A,
Marchese C, et al: DNMT3B in vitro knocking-down is able to reverse
embryonal rhabdomyosarcoma cell phenotype through inhibition of
proliferation and induction of myogenic differentiation.
Oncotarget. 7:79342–79356. 2016. View Article : Google Scholar
|
|
21
|
Han J, Lee JD, Jiang Y, Li Z, Feng L and
Ulevitch RJ: Characterization of the structure and function of a
novel MAP kinase kinase (MKK6). J Biol Chem. 271:2886–2891. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Remy G, Risco AM, Iñesta-Vaquera FA,
González-Terán B, Sabio G, Davis RJ and Cuenda A: Differential
activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal.
22:660–667. 2010. View Article : Google Scholar
|
|
23
|
Stramucci L, Pranteda A and Bossi G:
Insights of crosstalk between p53 protein and the MKK3/MKK6/p38
MAPK signaling pathway in cancer. Cancers (Basel). 10:1312018.
View Article : Google Scholar
|
|
24
|
Gardner S, Anguiano M and Rotwein P:
Defining Akt actions in muscle differentiation. Am J Physiol Cell
Physiol. 303:C1292–C1300. 2012. View Article : Google Scholar
|
|
25
|
Cabane C, Coldefy AS, Yeow K and Dérijard
B: The p38 pathway regulates Akt both at the protein and
transcriptional activation levels during myogenesis. Cell Signal.
16:1405–1415. 2004. View Article : Google Scholar
|
|
26
|
Bhatnagar S and Kumar A, Makonchuk DY, Li
H and Kumar A: Transforming growth factor-beta-activated kinase 1
is an essential regulator of myogenic differentiation. J Biol Chem.
285:6401–6411. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Davicioni E, Finckenstein FG, Shahbazian
V, Buckley JD, Triche TJ and Anderson MJ: Identification of a
PAX-FKHR gene expression signature that defines molecular classes
and determines the prognosis of alveolar rhabdomyosarcomas. Cancer
Res. 66:6936–6946. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marampon F, Gravina GL, Di Rocco A,
Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C,
Festuccia C, Popov VM, et al: MEK/ERK inhibitor U0126 increases the
radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by
downregulating growth and DNA repair signals. Mol Cancer Ther.
10:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miranda MB, McGuire TF and Johnson DE:
Importance of MEK-1/-2 signaling in monocytic and granulocytic
differentiation of myeloid cell lines. Leukemia. 16:683–692. 2002.
View Article : Google Scholar
|
|
30
|
Kurtzeborn K, Kwon HN and Kuure S:
MAPK/ERK signaling in regulation of renal differentiation. Int J
Mol Sci. 20:17792019. View Article : Google Scholar
|
|
31
|
Bellmann K, Martel J, Poirier DJ, Labrie
MM and Landry J: Downregulation of the PI3K/Akt survival pathway in
cells with deregulated expression of c-Myc. Apoptosis.
11:1311–1319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xie SJ, Li JH, Chen HF, Tan YY, Liu SR,
Zhang Y, Xu H, Yang JH, Liu S, Zheng LL, et al: Inhibition of the
JNK/MAPK signaling pathway by myogenesis-associated miRNAs is
required for skeletal muscle development. Cell Death Differ.
25:1581–1597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Raingeaud J, Whitmarsh AJ, Barrett T,
Dérijard B and Davis RJ: MKK3- and MKK6-regulated gene expression
is mediated by the p38 mitogen-activated protein kinase signal
transduction pathway. Mol Cell Biol. 16:1247–1255. 1996. View Article : Google Scholar
|
|
34
|
Perdiguero E, Ruiz-Bonilla V, Serrano AL
and Munoz-Canoves P: Genetic deficiency of p38alpha reveals its
critical role in myoblast cell cycle exit: The p38alpha-JNK
connection. Cell Cycle. 6:1298–1303. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Camero S, Vitali G, Pontecorvi P,
Ceccarelli S, Anastasiadou E, Cicchetti F, Flex E, Pomella S,
Cassandri M, Rota R, et al: DNMT3A and DNMT3B targeting as an
effective radiosensitizing strategy in embryonal rhabdomyosarcoma.
Cells. 10:29562021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gaestel M: MAPK-activated protein kinases
(MKs): Novel insights and challenges. Front Cell Dev Biol.
3:882015.
|
|
37
|
Serra C, Palacios D, Mozzetta C, Forcales
SV, Morantte I, Ripani M, Jones DR, Du K, Jhala US, Simone C and
Puri PL: Functional interdependence at the chromatin level between
the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle
differentiation. Mol Cell. 28:200–213. 2007. View Article : Google Scholar
|
|
38
|
Wu Z, Woodring PJ, Bhakta KS, Tamura K,
Wen F, Feramisco JR, Karin M, Wang JY and Puri PL: p38 and
extracellular signal-regulated kinases regulate the myogenic
program at multiple steps. Mol Cell Biol. 20:3951–3964. 2000.
View Article : Google Scholar
|
|
39
|
Xiao YQ, Malcolm K, Worthen GS, Gardai S,
Schiemann WP, Fadok VA, Bratton DL and Henson PM: Cross-talk
between ERK and p38 MAPK mediates selective suppression of
pro-inflammatory cytokines by transforming growth factor-beta. J
Biol Chem. 277:14884–14893. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shimo T, Matsumura S, Ibaragi S, Isowa S,
Kishimoto K, Mese H, Nishiyama A and Sasaki A: Specific inhibitor
of MEK-mediated cross-talk between ERK and p38 MAPK during
differentiation of human osteosarcoma cells. J Cell Commun Signal.
1:103–111. 2007. View Article : Google Scholar
|
|
41
|
Berra E, Diaz-Meco MT and Moscat J: The
activation of p38 and apoptosis by the inhibition of Erk is
antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol
Chem. 273:10792–10797. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Marampon F, Ciccarelli C and Zani BM:
Biological rationale for targeting MEK/ERK pathways in anti-cancer
therapy and to potentiate tumour responses to radiation. Int J Mol
Sci. 20:25302019. View Article : Google Scholar
|
